within Pharmacolibrary.Drugs.ATC.L;

model L01XX75
  extends Pharmacokinetic.Models.PK_1C_enteral(
    weight         = 70,
    F              = 1,
    Cl             = 0.043 / 1000 / 60,
    adminDuration  = 600,
    adminMass      = 68 / 1000000,
    adminCount     = 1,
    Vd             = 0.00263,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.016666666666666666,
    Tlag           = 600
  );

  annotation(Documentation(
    info ="<html><body><p>Tebentafusp is a bispecific fusion protein that targets glycoprotein 100 (gp100)-positive cells by redirecting T cells to recognize and destroy uveal melanoma cells. It is approved for the treatment of unresectable or metastatic uveal melanoma in adults.</p><h4>Pharmacokinetics</h4><p>Population pharmacokinetics in adult patients with metastatic uveal melanoma; both sexes; typical clinical dosing regimen.</p><h4>References</h4><ol><li><p>Wang, Z, et al., &amp; Chen, Y (2023). Tebentafusp: a novel drug for the treatment of metastatic uveal melanoma. <i>Drugs of today (Barcelona, Spain : 1998)</i> 59(3) 179â€“193. DOI:<a href=&quot;https://doi.org/10.1358/dot.2023.59.3.3542417&quot;>10.1358/dot.2023.59.3.3542417</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/36847626/&quot;>https://pubmed.ncbi.nlm.nih.gov/36847626</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>"
  ));
end L01XX75;
